CORPORATE INTEGRITY AGREEMENT
BETWEEN THE
OFFICE OF INSPECTOR GENERAL
OF THE
DEPARTMENT OF HEALTH AND HUMAN SERVICES
AND
ARTHREX, INC.

I. PREAMBLE

Arthrex, Inc. (Arthrex) hereby enters into this Corporate Integrity Agreement (CIA) with the Office of Inspector General (OIG) of the United States Department of Health and Human Services (HHS) to promote compliance with the statutes, regulations, and written directives of Medicare, Medicaid, and all other Federal health care programs (as defined in 42 U.S.C. § 1320a-7b(f)) (Federal health care program requirements) and with the statutes, regulations, and written directives of the Food and Drug Administration (FDA requirements). Arthrex represents that it has an established corporate compliance program which preceded the execution of this CIA. The compliance program includes a Compliance Officer, Compliance Committee, written policies and procedures, education and training programs, and a disclosure program. Arthrex will continue to operate its compliance program throughout the term of this CIA. Contemporaneously with this CIA, Arthrex is entering into a Settlement Agreement with the United States.

II. TERM AND SCOPE OF THE CIA

A. The Effective Date of this CIA shall be the date on which the final signatory of this CIA executes this CIA. The term of this CIA shall be five years from the Effective Date. Each one-year period, beginning with the one-year period following the Effective Date, shall be referred to as a “Reporting Period.”

B. Sections VII, X, and XI shall expire no later than 120 days after OIG’s receipt of: (1) Arthrex’s final Annual Report; or (2) any additional materials submitted by Arthrex pursuant to OIG’s request, whichever is later.

C. The scope of this CIA is governed by the following definitions:

1. For purposes of this CIA, the term “Covered Persons” includes: (a) all owners of Arthrex who are natural persons (other than shareholders who: (i) have an ownership interest of less than 5% and (ii) acquired the ownership interest through public trading); (b) all officers, directors and employees who are engaged in or who supervise personnel who are engaged in Covered Functions (as defined below in Section II.C.3) of
Arthrex; and (c) all contractors, subcontractors, agents, and other persons who perform any of the Covered Functions on behalf of Arthrex.

Notwithstanding the above, this term does not include part-time or per diem employees, contractors, subcontractors, agents, and other persons who are not reasonably expected to work more than 160 hours during a Reporting Period, except that any such individuals shall become “Covered Persons” at the point when they work more than 160 hours during a Reporting Period.

2. “Government Reimbursed Products” refers to all Arthrex products that are: (a) marketed or sold by Arthrex in the United States (or pursuant to contracts with the United States) and (b) reimbursed by Federal health care programs.

3. The term “Covered Functions” includes: (a) the selling, marketing, advertising, promoting, or branding of Government Reimbursed Products; (b) the preparation or external dissemination of promotional materials or information about, or the provision of services relating to, Government Reimbursed Products, including those functions relating to Arthrex’s review and approval processes for promotional materials and any applicable review committee(s); (c) the preparation or external dissemination of non-promotional materials about Government Reimbursed Products, including those functions relating to Arthrex’s review and approval process for any non-promotional materials and any applicable review committees; (d) contracting with health care professionals (HCPs) or health care institutions (HCIs) (health care institutions) for consulting services (including but not limited to speaker programs, speaker training programs, training and education services, product development activities, presentations, consultant task force meetings, advisory boards, ad hoc advisory activities, research and any research-related activities, and authorship of articles or other publications relating to Government Reimbursed Products), or other fee-for service arrangements relating to Government Reimbursed Products; (e) reviewing and/or approving requests for grants or charitable contributions; and (f) contracting with HCPs or HCIs for the purchase or licensing of intellectual property or for the payment of royalties for intellectual property contributions to the development of a product, technology, process or method.

4. The term “Sponsorships” shall mean support for a program, event, or organization in return for the advertisement, or promotion of Arthrex products, including healthcare-related conventions and conference sponsorships, promotional booths, exhibit space, advertisements, memberships, signage rights, naming rights, and subscriptions.

5. The term “Third Party Educational Activity” shall mean any scientific, educational, or professional program, meeting, or event for HCPs conducted by

Arthrex CIA
a third party and supported by Arthrex, including but not limited to, continuing medical education (CME), disease awareness, or sponsorship of symposia at medical conferences.

III. COMPLIANCE PROGRAM REQUIREMENTS

Arthrex shall establish and maintain a compliance program that includes the following elements:

A. Compliance Officer, Compliance Committee, Board of Directors Oversight, Independent Compliance Expert, and Management Certifications

1. **Compliance Officer.** Within 90 days after the Effective Date, Arthrex shall appoint a Compliance Officer and shall maintain a Compliance Officer for the term of the CIA. The Compliance Officer shall be an employee and a member of senior management of Arthrex; shall report directly to the President of Arthrex; and shall not be, or be subordinate to, the General Counsel or Chief Financial Officer or have any responsibilities that involve acting in any capacity as legal counsel or supervising legal counsel functions for Arthrex. The Compliance Officer shall be responsible for, without limitation:

   a. developing and implementing policies, procedures, and practices designed to ensure compliance with the requirements set forth in this CIA and with Federal health care program and FDA requirements;

   b. making periodic (at least quarterly) reports regarding compliance matters in person to the Arthrex Board of Directors (Board) and shall be authorized to report on such matters to the Board at any time. Written documentation of the Compliance Officer’s reports to the Board shall be made available to OIG upon request; and

   c. monitoring the day-to-day compliance activities engaged in by Arthrex as well as any reporting requirements created under this CIA.

Any noncompliance job responsibilities of the Compliance Officer shall be limited and must not interfere with the Compliance Officer’s ability to perform the duties outlined in this CIA.

Arthrex shall report to OIG, in writing, any changes in the identity of the Compliance Officer, or any actions or changes that would affect the Compliance

*Arthrex CIA*
Officer’s ability to perform the duties necessary to meet the requirements in this CIA, within five business days after such a change.

2. Compliance Committee. Within 90 days after the Effective Date, Arthrex shall appoint a Compliance Committee. The Compliance Committee shall, at a minimum, include the Compliance Officer and other members of senior management necessary to meet the requirements of this CIA (e.g., senior executives of relevant departments, such as sales, marketing, legal, medical affairs/medical information, regulatory affairs, research and development, human resources, audit, finance, manufacturing, and operations). The Compliance Officer shall chair the Compliance Committee and the Compliance Committee shall support the Compliance Officer in fulfilling his/her responsibilities (e.g., shall assist in the analysis of Arthrex’s risk areas and shall oversee monitoring of internal and external audits and investigations). The Compliance Committee shall meet at least quarterly. The minutes of the Compliance Committee meetings shall be made available to OIG upon request.

Arthrex shall report to OIG, in writing, any actions or changes that would affect the Compliance Committee’s ability to perform the duties necessary to meet the requirements in this CIA, within 15 business days after such a change.

3. Board of Directors Oversight. The Board shall be responsible for the review and oversight of matters related to compliance with Federal health care program requirements, FDA requirements, and the requirements of this CIA.

The Board shall, at a minimum, be responsible for the following:

a. meeting at least quarterly to review and oversee Arthrex’s compliance program, including but not limited to the performance of the Compliance Officer and Compliance Committee;

b. submitting to OIG a description of the documents and other materials it reviewed, as well as any additional steps taken, such as the engagement of an independent advisor or other third party resources, in its oversight of the compliance program and in support of making the resolution below during each Reporting Period; and

c. for each Reporting Period of the CIA, adopting a resolution, signed by each member of the Board, summarizing its review and oversight of Arthrex’s compliance with Federal health
care program requirements, FDA requirements, and the requirements of this CIA.

At minimum, the resolution shall include the following language:

“The Board has made a reasonable inquiry into the operations of Arthrex’s compliance program including the performance of the Compliance Officer and the Compliance Committee. Based on its inquiry and review, the Board has concluded that, to the best of its knowledge, Arthrex has implemented an effective compliance program to meet Federal health care program requirements, FDA requirements, and the requirements of the Corporate Integrity Agreement.”

If the Board is unable to provide such a conclusion in the resolution, the Board shall include in the resolution a written explanation of the reasons why it is unable to provide the conclusion and the steps it is taking to implement an effective compliance program at Arthrex.

Arthrex shall report to OIG, in writing, any changes in the composition of the Board, or any actions or changes that would affect the Board’s ability to perform the duties necessary to meet the requirements in this CIA, within 15 business days after such a change.

4. **Independent Compliance Expert.** Within 90 days after the Effective Date, Arthrex shall retain an individual or entity with expertise in compliance with Federal health care program and FDA requirements (Compliance Expert) to perform a review of the effectiveness of Arthrex’s compliance program (Compliance Program Review) for each Reporting Period of the CIA. The Compliance Expert must not represent or be employed or engaged by Arthrex and must not have a current or prior relationship to Arthrex, Arthrex’s Board members, or Arthrex’s owners that would cause a reasonable person to question the Compliance Expert’s objectivity in performing the Compliance Program Review. The Compliance Expert shall prepare a written report of its Compliance Program Review (Compliance Program Review Report) which shall include a description of the Compliance Program Review and any findings and recommendations with respect to Arthrex’s compliance program. The Board shall review the Compliance Program Review Report as part of its review and oversight of Arthrex’s compliance program. A copy of the Compliance Program Review report shall be provided to OIG in each Annual Report submitted by Arthrex, along with a certification from the Compliance Expert that it does not have a prohibited relationship with Arthrex or its owners as set forth above and a summary of any current and prior relationships with Arthrex, its Board members, or its owners.

*Arthrex CIA*
5. **Management Certifications.** In addition to the responsibilities set forth in this CIA for all Covered Persons, certain Arthrex employees (Certifying Employees) are specifically expected to monitor and oversee activities within their areas of authority and shall annually certify that the applicable Arthrex business unit is in compliance with applicable Federal health care program and FDA requirements and with the requirements of this CIA. These Certifying Employees shall include, at a minimum, the following: the President; the Vice President of Finance; the Senior Vice President of Sales for the United States and Canada; the Vice President of Engineering; the Senior Vice President and General Counsel; the Director of Orthopedic Research; the Vice President of Risk Management & Compliance; the Chief Intellectual Property Counsel; the Vice President of Regulatory Affairs and Quality Assurance; the Vice President of Strategic Development; the Vice President of Global Medical Education; and the Vice President of Information Technology.

For each Reporting Period, each Certifying Employee shall sign a certification that states:

“I have been trained on and understand the compliance requirements and responsibilities as they relate to [insert name of department], an area under my supervision. My job responsibilities include ensuring compliance with regard to the [insert name of the department] with all applicable Federal health care program requirements, FDA requirements, requirements of the Corporate Integrity Agreement, and Arthrex policies, and I have taken steps to promote such compliance. To the best of my knowledge, the [insert name of department] of Arthrex complies with all applicable Federal health care program requirements, FDA requirements, and the requirements of the Corporate Integrity Agreement. I understand that this certification is being provided to and relied upon by the United States.”

If any Certifying Employee is unable to provide such a certification, the Certifying Employee shall provide a written explanation of the reasons why he or she is unable to provide the certification outlined above.

Within 90 days after the Effective Date, Arthrex shall develop and implement a written process for Certifying Employees to follow for the purpose of completing the certification required by this section (e.g., reports that must be reviewed, assessments that must be completed, sub-certifications that must be obtained, etc. prior to the Certifying Employee making the required certification).

*Arthrex CIA*
B. Written Standards

1. **Policies and Procedures.** Within 90 days after the Effective Date, Arthrex shall develop and implement written policies and procedures regarding the operation of its compliance program, including the compliance program requirements outlined in this CIA and Arthrex’s compliance with Federal health care program and FDA requirements (Policies and Procedures). Throughout the term of this CIA, Arthrex shall enforce its Policies and Procedures and shall make compliance with its Policies and Procedures an element of evaluating the performance of all employees. The Policies and Procedures shall be made available to all Covered Persons. At a minimum, the Policies and Procedures shall address the following:

   a. appropriate ways to conduct Covered Functions in compliance with all: (i) applicable Federal healthcare program requirements, including, but not limited to the Federal Anti-Kickback Statute (codified at 42 U.S.C. § 1320a-7b(b)) and the False Claims Act (codified at 31 U.S.C. §§ 3729-3733); and (ii) all applicable FDA requirements;

   b. the materials and information that may be distributed by Arthrex sales representatives (including any contract sales force) about Government Reimbursed Products and the manner in which Arthrex sales representatives respond to requests for information about uses of Government Reimbursed Products that are not FDA approved, cleared or exempt (“non-FDA approved uses”);

   c. the materials and information that may be distributed and the mechanisms through, and manner in which, Arthrex receives and responds to requests for information from an HCP or another individual or entity about non-FDA approved uses of Government Reimbursed Products; the form and content of information disseminated by Arthrex in response to such requests; and the internal review process for the information disseminated;

   d. the manner and circumstances under which Arthrex medical personnel interact with or participate in meetings or events with HCPs, HCIs, or payors (either alone or with Arthrex sales representatives) and the role of Arthrex medical personnel at such meetings or events, as well as how they
handle responses to requests for information about non-FDA approved uses of Government Reimbursed Products;

e. the materials and information that may be distributed or made available by Arthrex through social media and/or direct-to-consumer advertising;

f. the development, implementation, and review of policies for the distribution of Government Reimbursed Products for evaluation purposes (Evaluation Product). This shall include a review of the bases upon, and circumstances under, which HCPs and HCIs belonging to specified medical specialties or types of clinical practice may receive Evaluation Product from Arthrex (including, separately, from sales representatives, or through other channels);

g. consultant or other fee-for-service arrangements entered into with HCPs or HCIs (including but not limited to speaker programs, speaker training programs, training and education services, product development activities, presentations, consultant task force meetings, advisory boards, ad hoc advisory activities, research and research-related activities, authorship activities, and any other financial engagement or arrangement with an HCP or HCI) and all events and expenses relating to such engagements or arrangements;

h. agreements or arrangements with HCPs or HCIs for the purchase or licensing of intellectual property or for the payment of royalties for intellectual property contributions to the development of a product, technology, process or method;

i. programs by HCPs to educate sales representatives, including but not limited to presentations by HCPs at sales meetings, preceptorships, tutorials, and experience-based learning activities;

j. review and approval of, and payment for, travel and related expenses for HCPs including those in connection with HCP participation in educational, research, training, or other Arthrex-sponsored programs or activities;
k. sponsorship or funding of grants (including educational grants) or charitable contributions involving HCPs and HCIs;

l. funding of, or participation in, any Sponsorships or Third Party Educational Activity as defined in Section II.C.4 and II.C.5 above;

m. review of promotional, reimbursement-related, and disease state materials and information intended to be disseminated outside Arthrex by appropriate qualified personnel (such as regulatory, medical, and/or legal personnel) in a manner designed to ensure that legal, regulatory, and medical concerns are properly addressed during Arthrex’s review and approval process and are elevated when appropriate;

n. compensation (including through salaries, bonuses, or other means) for Covered Persons who are sales representatives and their managers; and

o. disciplinary policies and procedures for violations of Arthrex’s Policies and Procedures, including policies relating to Federal health care program and FDA requirements.

At least annually (and more frequently, if appropriate), Arthrex shall assess and update, as necessary, the Policies and Procedures. Any new or revised Policies and Procedures shall be made available to all Covered Persons.

All Policies and Procedures shall be made available to OIG upon request.

C. Training and Education

1. Covered Persons Training. Within 90 days after the Effective Date, Arthrex shall develop a written plan (Training Plan) that outlines the steps Arthrex will take to ensure that: (a) all Covered Persons receive at least annual training regarding Arthrex’s CIA requirements and compliance program, and (b) all Covered Persons who engage in Covered Functions receive at least annual training regarding: (i) all applicable Federal health care program and FDA requirements relating to Covered Functions and (ii) all Arthrex Policies and Procedures and other requirements applicable to Covered Functions. The Training Plan shall include information regarding the following: training topics, categories of Covered Persons and required to attend each training session, length of the training session(s), schedule for training, and format of the training. Arthrex shall
furnish training to its Covered Persons pursuant to the Training Plan during each Reporting Period.

2. **Board Training.** In addition to the training described in Section III.C.1, within 90 days after the Effective Date, each member of the Board shall receive training regarding the corporate governance responsibilities of board members, and the responsibilities of board members with respect to review and oversight of the compliance program. Specifically, the training shall address the unique responsibilities of health care board members, including the risks, oversight areas, and strategic approaches to conducting oversight of a health care entity. This training may be conducted by an outside compliance expert hired by the Board and should include a discussion of OIG’s guidance on board member responsibilities.

   New members of the Board shall receive the Board Training described above within 30 days after becoming a member or within 90 days after the Effective Date, whichever is later.

3. **Training Records.** Arthrex shall make available to OIG, upon request, training materials and records verifying that the training described in Sections III.C.1 III.C.2 has been provided as required.

D. **Risk Assessment and Internal Review Process**

   Within 90 days after the Effective Date, Arthrex shall develop and implement a centralized annual risk assessment and internal review process to identify and address risks associated with each Government Reimbursed Product, including risks associated with the Covered Functions. The Compliance Committee shall be responsible for implementation and oversight of the risk assessment and internal review process. The risk assessment and internal review process shall be conducted annually and shall require Arthrex to: (1) identify and prioritize risks, (2) develop internal audit work plans related to the identified risk areas, (3) implement the internal audit work plans, (4) develop corrective action plans in response to the results of any internal audits performed, and (5) track the implementation of the corrective action plans in order to assess the effectiveness of such plans. Arthrex shall maintain the risk assessment and internal review process for the term of the CIA.

E. **Review Procedures**

   1. **General Description.**
a. **Engagement of Independent Review Organization.** Within 90 days after the Effective Date, Arthrex shall engage an entity (or entities), such as an accounting, auditing, or consulting firm (hereinafter “Independent Review Organization” or “IRO”), to perform the reviews listed in this Section III.E. The applicable requirements relating to the IRO are outlined in Appendix A to this CIA, which is incorporated by reference.

b. **Retention of Records.** The IRO and Arthrex shall retain and make available to OIG, upon request, all work papers, supporting documentation, correspondence, and draft reports (those exchanged between the IRO and Arthrex) related to the reviews.

c. **Access to Records and Personnel.** Arthrex shall ensure the IRO has access to all records and personnel necessary to complete the reviews listed in this Section III.E., and that all records furnished to the IRO are accurate and complete.

2. **Systems Review and Transactions Review.** As set forth more fully in Appendix B, the IRO reviews shall consist of two components: a Systems Review and a Transactions Review relating to the Covered Functions.

a. **Systems Review.** The Systems Review shall assess Arthrex’s systems, processes, policies, and procedures relating to the Covered Functions. If there are no material changes in Arthrex’s relevant systems, processes, policies, and procedures, the Systems Review shall be performed for the first and fourth Reporting Periods. If Arthrex materially changes its relevant systems, processes, policies, and procedures, the IRO shall perform a Systems Review for the Reporting Period in which such changes were made in addition to conducting the Systems Review for the first and fourth Reporting Periods, as set forth more fully in Appendix B.

b. **Transactions Review.** The Transactions Review shall be performed annually and shall cover each of the five Reporting Periods. The IRO(s) shall perform all components of each annual Transaction Review. As set forth more fully in...
Appendix B, the Transactions Review shall include several components.

3. **IRO Review Report.** The IRO shall prepare a report based upon each IRO review performed (IRO Review Report). Information to be included in the IRO Review Report is described in Appendices A-B.

4. **Independence and Objectivity Certification.** The IRO shall include in its report(s) to Arthrex a certification that the IRO has: (a) evaluated its professional independence and objectivity with respect to the reviews required under this Section III.E; and (b) concluded that it is, in fact, independent and objective in accordance with the requirements specified in Appendix A to this CIA. The IRO’s certification shall include a summary of current and prior engagements between Arthrex and IRO.

F. **Disclosure Program**

Within 90 days after the Effective Date, Arthrex shall establish a Disclosure Program that includes a mechanism (e.g., a toll free compliance telephone line) to enable individuals to disclose, to the Compliance Officer or some other person who is not in the disclosing individual’s chain of command, any identified issues or questions associated with Arthrex’s policies, conduct, practices, or procedures with respect to a Federal health care program or an FDA requirement believed by the individual to be a potential violation of criminal, civil, or administrative law. Arthrex shall appropriately publicize the existence of the Disclosure Program and the disclosure mechanism (e.g., via periodic e-mails to employees, or by posting the information in prominent common areas).

The Disclosure Program shall emphasize a nonretribution, nonretaliation policy and shall include a reporting mechanism for anonymous communications for which appropriate confidentiality shall be maintained. The Disclosure Program also shall include a requirement that all of Arthrex’s Covered Persons shall be expected to report suspected violations of any Federal health care program or FDA requirements to the Compliance Officer or other appropriate individual designated by Arthrex. Upon receipt of a disclosure, the Compliance Officer (or designee) shall gather all relevant information from the disclosing individual. The Compliance Officer (or designee) shall make a preliminary, good faith inquiry into the allegations set forth in every disclosure to ensure that he or she has obtained all of the information necessary to determine whether a further review should be conducted. For any disclosure that is sufficiently specific so that it reasonably: (1) permits a determination of the appropriateness of the alleged improper practice; and (2) provides an opportunity for taking corrective action, Arthrex shall conduct an internal review of the allegations set forth in the disclosure and ensure that proper follow-up is conducted.

*Arthrex CIA*
The Compliance Officer (or designee) shall maintain a disclosure log and shall record all disclosures, whether or not related to a potential violation of criminal, civil or administrative law related to Federal health care programs or FDA requirements, in the disclosure log within two business days of receipt of the disclosure. The disclosure log shall include a summary of each disclosure received (whether anonymous or not), the individual or department responsible for reviewing the disclosure, the status of the review, and any corrective action taken in response to the review.

G. Ineligible Persons

1. Definitions. For purposes of this CIA:

   a. an “Ineligible Person” shall include an individual or entity who:

      i. is currently excluded from participation in the Federal health care programs; or

      ii. has been convicted of a criminal offense that falls within the scope of 42 U.S.C. § 1320a-7(a) but has not yet been excluded.


2. Screening Requirements. Arthrex shall ensure that all prospective and current Covered Persons are not Ineligible Persons by implementing the following screening requirements.

   a. Arthrex shall screen all prospective Covered Persons against the Exclusion List prior to engaging their services and, as part of the hiring or contracting process, shall require such Covered Persons to disclose whether they are Ineligible Persons.

   b. Arthrex shall screen all current Covered Persons against the Exclusion List within 90 days after the Effective Date and on an annual basis thereafter.

Arthrex CIA
c. Arthrex shall maintain a policy requiring all Covered Persons to disclose immediately if they become an Ineligible Person.

Nothing in this Section III.G affects Arthrex’s responsibility to refrain from (and liability for) billing Federal health care programs for items or services furnished, ordered, or prescribed by an excluded person. Arthrex understands that items or services furnished, ordered, or prescribed by excluded persons are not payable by Federal health care programs and that Arthrex may be liable for overpayments and/or criminal, civil, and administrative sanctions for employing or contracting with an excluded person regardless of whether Arthrex meets the requirements of Section III.G.

3. Removal Requirement. If Arthrex has actual notice that a Covered Person has become an Ineligible Person, Arthrex shall remove such Covered Person from responsibility for, or involvement with, Arthrex’s business operations related to the Federal health care program(s) from which such Covered Person has been excluded and shall remove such Covered Person from any position for which the Covered Person’s compensation is paid in whole or part, directly or indirectly, by any Federal health care program(s) from which the Covered Person has been excluded at least until such time as the Covered Person is reinstated into participation in such Federal health care program(s).

4. Pending Charges and Proposed Exclusions. If Arthrex has actual notice that a Covered Person is charged with a criminal offense that falls within the scope of 42 U.S.C. §§ 1320a-7(a), 1320a-7(b)(1)-(3), or is proposed for exclusion during the Covered Person’s employment or contract term, Arthrex shall take all appropriate actions to ensure that the responsibilities of that Covered Person have not and shall not adversely affect the quality of care rendered to any beneficiary, or the accuracy of any claims submitted to any Federal health care program.

H. Notification of Government Investigation or Legal Proceeding

Within 30 days after discovery, Arthrex shall notify OIG, in writing, of any ongoing investigation or legal proceeding known to Arthrex conducted or brought by a governmental entity or its agents involving an allegation that Arthrex has committed a crime or has engaged in fraudulent activities. This notification shall include a description of the allegation, the identity of the investigating or prosecuting agency, and the status of such investigation or legal proceeding. Arthrex also shall provide written notice to OIG within 30 days after the resolution of the matter and describe the findings and/or results of the investigation or proceeding, if any.
I. Reportable Events

1. Definition of Reportable Event. For purposes of this CIA, a “Reportable Event” means anything that involves:

a. a matter that a reasonable person would consider a probable violation of criminal, civil, or administrative laws applicable to any Federal health care program for which penalties or exclusion may be authorized;

b. a matter that a reasonable person would consider a probable violation of FDA requirements relating to the marketing or sale of Government Reimbursed Products, unless otherwise reported to the FDA in accordance with Section III.J below;

c. the employment of or contracting with a Covered Person who is an Ineligible Person as defined by Section III.G.1.a; or

d. the filing of a bankruptcy petition by Arthrex.

A Reportable Event may be the result of an isolated event or a series of occurrences.

2. Reporting of Reportable Events. If Arthrex determines (after a reasonable opportunity to conduct an appropriate review or investigation of the allegations) through any means that there is a Reportable Event, Arthrex shall notify OIG, in writing, within 30 days after making the determination that the Reportable Event exists.

3. Reportable Events under Sections III.I.1.a and III.I.1.b. For Reportable Events under Sections III.I.1.a and b, the report to OIG shall include:

a. a complete description of all details relevant to the Reportable Event, including, at a minimum, the types of claims, transactions or other conduct giving rise to the Reportable Event, the period during which the conduct occurred, and the names of individuals and entities believed to be implicated, including an explanation of their roles in the Reportable Event;
b. a statement of the Federal criminal, civil or administrative laws that are probably violated by the Reportable Event, if any;

c. the Federal health care programs affected by the Reportable Event, if any;

d. a statement of the FDA requirements probably violated by the Reportable Event, if any; and

e. a description of Arthrex’s actions taken to correct the Reportable Event and prevent it from recurring.

4. Reportable Events under Section III.I.1.c. For Reportable Events under Section III.I.1.c, the report to OIG shall include:

a. the identity of the Ineligible Person and the job duties performed by that individual;

b. the dates of the Ineligible Person’s employment or contractual relationship;

c. a description of the Exclusion List screening that Arthrex completed before and/or during the Ineligible Person’s employment or contract and any flaw or breakdown in the screening process that led to the hiring or contracting with the Ineligible Person;

d. a description of how the Ineligible Person was identified; and

e. a description of any corrective action implemented to prevent future employment or contracting with an Ineligible Person.

5. Reportable Events under Section III.I.1.d. For Reportable Events under Section III.I.1.d, the report to OIG shall include documentation of the bankruptcy filing and a description of any Federal health care program and/or FDA requirements implicated.
J. Notification of Communications with FDA

Within 30 days after the date of any written report, correspondence, or communication between Arthrex and the FDA that materially discusses Arthrex’s or a Covered Person’s actual or potential unlawful or improper marketing or sale of Arthrex’s products, Arthrex shall provide a copy of the report, correspondence, or communication to OIG. Arthrex shall also provide written notice to OIG within 30 days after the resolution of any such disclosed matter and shall provide OIG with a description of the findings and/or results of the matter, if any.

K. Requirements Relating to Speaker Programs

Within 90 days following the Effective Date, Arthrex shall establish and implement the following requirements relating to arrangements with HCPs to serve as presenters on behalf of Arthrex or participate in training programs related to such presentations (Speaker Programs).

1. An annual budget and needs assessment process that identifies the business needs for, and the estimated numbers of, speaker program activities for the following year. As part of the process, Arthrex shall identify the business need for the planned speaker programs and shall collect specific details about the speaker programs (e.g., the expected number of programs, the topics of the programs, and the identity and qualifications of the proposed speakers.) The annual speaker program budget shall identify the total budgeted amounts to be spent on speaker programs. Arthrex compliance personnel shall be involved in the review and approval of such plans, including any subsequent modification of approved plans. The purpose of this review shall be to ensure that speaker programs and related events (including speaker training events) are used for legitimate and lawful purposes in accordance with applicable Federal health care program and FDA requirements and Arthrex Policies and Procedures.

2. A process to require all speakers to complete training and enter written agreements that describe the scope of work to be performed, the speaker fees to be paid, and compliance requirements for the speakers (including requirements regarding the use of Arthrex approved materials and requirements that speakers may not directly or indirectly promote the product for non-FDA approved uses).

3. A centralized, electronic system to initiate and track all speaker programs that includes controls designed to ensure that speaker programs are used for legitimate and lawful purposes in accordance with all applicable Federal health care program and FDA requirements.

Arthrex CIA
4. A process to ensure speakers are paid according to a centrally managed, pre-set rate structure determined based on an independent fair-market value analysis.

5. A comprehensive list of speaker program attendees through its centralized system. In addition, Arthrex shall use its centralized system to handle all logistics and spending associated with speaker programs, including the tracking and review of the aggregate amount (including speaker fees, travel, and other expenses) paid to each speaker in connection with speaker programs.

6. A requirement for certifications by sales representatives or other Arthrex personnel that a speaker program complied with Arthrex requirements, or in the event of non-compliance, Arthrex shall require the identification of the policy violation and ensure appropriate follow up activity to address the violation.

7. A Speaker Monitoring Program under which Arthrex compliance or other appropriately trained Arthrex personnel who are independent from the functional area being monitored (Monitoring Personnel) shall attend three speaker programs during each Reporting Period and conduct live audits of the programs (Speaker Program Audits). The programs subject to Speaker Program Audits shall be selected using either a risk-based targeting approach or a random sampling approach. For each program reviewed, Monitoring Personnel shall review slide materials and other materials used as part of the speaker program, speaker statements made during the program, and Arthrex sales representative activities during the program to assess whether the programs were conducted in a manner consistent with Arthrex’s Policies and Procedures. Results from the Speaker Monitoring Program shall be compiled and reported to the Compliance Officer for review and remediation as appropriate.

L. Field Force Monitoring and Review Efforts

Within 90 days after the Effective Date, Arthrex shall establish a comprehensive Field Force Monitoring Program (FFMP) to evaluate and monitor its sales personnel’s interactions with HCPs and HCIs. The FFMP shall be a formalized process designed to directly and indirectly observe the appropriateness of sales personnel’s interactions with HCPs and HCIs and to identify potential improper promotional activities or other improper conduct. As described in more detail below, the FFMP shall include: (1) direct field observations (Observations) of sales personnel and (2) the monitoring and review of other records relating to sales personnel’s interactions with HCPs and HCIs (Records Reviews).

Arthrex CIA
1. Observations. As a component of the FFMP, Monitoring Personnel shall conduct observations of sales representatives (including any contract sales personnel) to assess whether the messages delivered, and materials distributed to HCPs and HCIs are consistent with applicable legal requirements and with Arthrex’s Policies and Procedures. These observations shall be full day “ride-alongs” with sales representatives (Observations), and each Observation shall consist of directly observing all meetings between a sales representative and HCPs and HCIs during the workday. The Observations shall be scheduled throughout the year, judgmentally selected by Monitoring Personnel, and be conducted across the United States.

At the completion of each Observation, Monitoring Personnel shall prepare a report which includes: (a) the identity of the sales representative; (b) the identity of the Monitoring Personnel who conducted the Observation; (c) the date and duration of the Observation; (d) the product(s) promoted during the Observation; (e) an overall assessment of compliance with Arthrex Policies and Procedures; and (f) the identification of any potential improper promotional activity or other improper conduct by the field sales representative.

Monitoring Personnel shall conduct at least 50 Observations during each Reporting Period. Monitoring Personnel shall have access to all relevant records and information necessary to assess sales representatives’ interactions with HCPs and HCIs and to identify potential or actual compliance violations.

2. Records Reviews. As a component of the FFMP, Arthrex shall also review various types of records to assess sales representatives’ interactions with HCPs and HCIs and to identify potential or actual compliance violations.

a. For each Reporting Period, Arthrex shall develop and implement a plan for conducting Records Reviews associated with at least five Government Reimbursed Product Lines. The Records Reviews shall include a review of records relating to the activities of sales representatives in every separate district and/or region (as applicable) who promoted the products under review.

b. The Records Reviews shall include the monitoring and review of:

---

1 The “Government Reimbursed Product Lines” are the categories of Arthrex Part Type Subsets, which group together related products and components to form distinct products associated with their applications (e.g., Shoulder, Knee & Hip, Arthroplasty, Distal Extremities).

*Arthrex CIA*
(i) records and systems associated with sales representatives’ interactions with HCPs and HCIs (including records relating to consulting and other fee-for-service arrangements, speaker program activities, travel and entertainment, expense reports, any payments to HCPs or HCIs, and sales communications from managers);

(ii) records relating to requests for medical information about or inquiries relating to, the Government Reimbursed Products under review;

(iii) sales representative call notes;

(iv) sales representatives’ e-mails and other electronic records; and

(v) recorded results of the Observations of sales force representatives, coaching guides, and manager notes.

3. Reporting and Follow-up. Results from the FFMP shall be compiled and reported to the Compliance Officer for review and remediation as appropriate.

M. Requirements Relating to Certain Non-Promotional Activities

Within 90 days after the Effective Date, Arthrex shall develop policies, procedures, and systems to implement the requirements outlined below relating to the following types of activities: (1) consultant arrangement activities; (2) grant and charitable contribution activities involving HCPs and HCIs; and intellectual property agreement activities involving HCPs and HCIs.

1. Consulting Arrangement Activities. To the extent that Arthrex engages HCPs, either directly or indirectly (e.g., through local distributors on behalf of Arthrex), for services other than for speaker programs (e.g., training and education services, product development activities, presentations, consultant task force meetings, advisory boards, ad hoc advisory activities, research and research-related activities, authorship activities, and any other financial engagement or arrangement with an HCP), such HCPs shall be referred to herein as Consultants. Within 90 days of the Effective Date, Arthrex shall:

Arthrex CIA
a. Require all Consultants to enter written agreements describing the scope of work to be performed, the consultant fees to be paid, and compliance requirements for the Consultants. Consultants shall be paid according to a centrally managed, pre-set rate structure that is determined based on an independent fair-market value analysis.

b. Establish a process to develop an annual budgeting plan that specifies (i) the business needs for, and the estimated numbers of, the various Consultant engagements and activities to occur during the following year and (ii) the budgeted amounts to be spent on Consultant-related activities. Arthrex compliance personnel shall be involved in the review and approval of such plans, including any subsequent modification of an approved plan for the purpose of ensuring that Consultant arrangements and related events are used for legitimate and lawful purposes in accordance with applicable Federal health care program and FDA requirements and Arthrex Policies and Procedures.

c. Establish a process to ensure that a needs assessment has been completed to justify the retention of a Consultant prior to the retention of the Consultant. The needs assessment shall identify the business need for the retention of the Consultant and provide specific details about the consulting arrangement (e.g., information about the numbers and qualifications of the HCPs and HCIs to be engaged, the agenda for the proposed meeting, and a description of the proposed work to be done and the type of work product to be generated). Any deviations from the Consultant budgeting plans shall be documented in the needs assessment form and shall be subject to review and approval by Arthrex compliance personnel.

d. Amend its policies and procedures in a manner designed to ensure that each Consultant performs the work for which the Consultant is engaged and that, as applicable, Arthrex receives the work product generated by the Consultant.
2. **Grant and Charitable Contribution Activities.** Within 90 days of the Effective Date, Arthrex shall:

   a. Establish a centralized system which shall be the exclusive mechanism through which requestors may request or be awarded amounts for Third Party Educational Activities, other grant activities involving HCPs and HCIs (referred to below as “Grants”), and charitable contributions involving HCPs and HCIs supported by Arthrex (referred to below as “Contributions”).

   b. Establish a process to review requests for Grants and Contributions according to standardized, objective criteria developed by Arthrex (such as based upon the qualifications of the requestor, or the quality of the program funded by the Grant or Contribution) and to ensure that Grants or Contributions are provided only pursuant to a written agreement with the funding recipient and that payments to the funding recipient are consistent with the written agreement. Arthrex’s sales and marketing personnel shall not be involved in, or influence, the review and approval of requests for Grants or Contributions.

3. **Intellectual Property Arrangements.** Within 90 days of the Effective Date, Arthrex shall:

   a. Develop policies, procedures, and systems relating to agreements or arrangements with HCPs or HCIs for the purchase or licensing of intellectual property or for the payment of royalties for intellectual property contributions to a product, technology, process, or method (“Intellectual Property Arrangements”).

   b. Ensure that any agreement or arrangement with an HCP or HCI for the purchase or licensing of intellectual property or for the payment of royalties is in writing and describes the intellectual property to be licensed or purchased, or the novel, significant, or innovative intellectual property contribution; and the purchase price, licensing fees, or royalties to be paid. Any such purchase price, licensing fees, or royalty rates must
be determined based on an independent fair market value analysis.

c. Establish a process to develop an annual budgeting plan for the purchase or licensing of intellectual property from HCPs or HCIs or for the payment of royalties to HCPs or HCIs that identifies the business or scientific need or scientific opportunity for, and the estimated numbers of, the various Intellectual Property Arrangements to be entered into during the year. The annual budgeting plan shall also identify the budgeted amounts to be spent on Intellectual Property Arrangements during the year. Arthrex compliance personnel shall be involved in the review and approval of such budgeting plans, including any subsequent modification of an approved plan, for the purpose of ensuring that Intellectual Property Arrangements are entered into for legitimate purposes in accordance with Arthrex Policies and Procedures and with Federal health care program and FDA requirements.

d. Arthrex shall establish a process to ensure that a needs assessment has been completed to justify any Intellectual Property Arrangement prior to entering into the Intellectual Property Arrangement. The needs assessment shall identify the business or scientific need for the intellectual property to be licensed or purchased or for the intellectual property contribution for which royalties will be paid. Any deviations from the budgeting plans shall be documented in the needs assessment form (or elsewhere, as appropriate) and shall be subject to review and approval by Arthrex compliance personnel.

N. Reporting of Physician Payments

1. **Reporting of Payment Information.** Within 90 days after the Effective Date, Arthrex shall post on its website a description of the types of Payments it makes to Covered Recipients and include a link to CMS’s Open Payments Data website ([www.openpaymentsdata.cms.gov](http://www.openpaymentsdata.cms.gov)). Arthrex also shall include on its website instructions regarding how to utilize the CMS Open Payments Data search tool to search for information regarding Payments provided to Covered Recipients from Arthrex.
2. **Definitions.** For purposes of this Section III.N, the terms “Payments” and “Covered Recipient” are defined as specified in 42 U.S.C. § 1320a-7h and the related regulations and guidance (including FAQs) published by CMS.

**IV. SUCCESSOR LIABILITY**

In the event that, after the Effective Date, Arthrex proposes to (a) sell any or all of its business, business units or locations (whether through a sale of assets, sale of stock or other type of transaction) that are subject to this CIA; or (b) purchases or establishes a new business, business unit or location related to or engaged in any of the Covered Functions, the CIA shall be binding on the purchaser of any business, business unit or location. Any such new business, business unit or location (and all Covered Persons at each new business, business unit or location) shall be subject to the applicable requirements of this CIA, unless otherwise determined and agreed to in writing by OIG. Arthrex shall give notice of such sale or purchase to OIG within 30 days following the closing of the transaction.

If, in advance of a proposed sale or a proposed purchase, Arthrex wishes to obtain a determination by OIG that the proposed purchaser or the proposed acquisition will not be subject to the requirements of the CIA, Arthrex must notify OIG in writing of the proposed sale or purchase at least 30 days in advance. This notification shall include a description of the business, business unit, or location to be sold or purchased, a brief description of the terms of the transaction and, in the case of a proposed sale, the name and contact information of the prospective purchaser.

**V. IMPLEMENTATION AND ANNUAL REPORTS**

A. **Implementation Report**

Within 120 days after the Effective Date, Arthrex shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:

1. the name, business address, business phone number, and position description of the Compliance Officer required by Section III.A.1, and a summary of other noncompliance job responsibilities the Compliance Officer may have;

2. the names and positions of the members of the Compliance Committee required by Section III.A.2;

Arthrex CIA
3. the names of the Board members who are responsible for satisfying the Board compliance requirements described in Section III.A.3;

4. the following information regarding the Compliance Expert required by Section III.A.4: (a) identity, address, and phone number; (b) a copy of the engagement letter between Arthrex and the Compliance Expert; (c) information regarding the Compliance Expert’s expertise in compliance with Federal health care program and FDA requirements; and (d) a certification from the Compliance Expert that they do not have a prohibited relationship with Arthrex, its Board members, or its owners (as defined in Section III.A.4) and a summary of any current and prior relationships with Arthrex, its Board members, or its owners;

5. the names and positions of the Certifying Employees required by Section III.A.5 and a copy of the written process for Certifying Employees to follow in order to complete the certification required by Section III.A.5;

6. a list of the Policies and Procedures required by Section III.B.1;

7. the Training Plan required by Section III.C.1 and a description of the Board of Directors training required by Section III.C.2 (including a summary of the topics covered, the length of the training and when the training was provided);

8. a description of the risk assessment and internal review process required by Section III.D;

9. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; and (d) a certification from the IRO regarding its professional independence and objectivity with respect to Arthrex that includes a summary of all current and prior engagements between Arthrex and the IRO;

10. a description of the Disclosure Program required by Section III.F;

11. a description of the Ineligible Persons screening and removal process required by Section III.G;

12. a description of policies, procedures, and systems implemented pursuant to the Requirements Relating to Speaker Programs outlined in Section III.K;

13. a description of the FFMP required by Section III.L;
14. a description of the policies, procedures, and systems implemented pursuant to the Requirements Relating to Certain Non-Promotional Activities outlined in Section III.M;

15. a certification from the Compliance Officer that information regarding Payments has been posted on Arthrex’s website as required by Section III.N;

16. a list of all of Arthrex’s locations (including locations and mailing addresses); the corresponding name under which each location is doing business; and the locations’ Medicare and state Medicaid provider number and/or supplier number(s) if any;

17. a description of Arthrex’s corporate structure, including identification of any parent and sister companies, subsidiaries, and their respective lines of business; and

18. the certifications required by Section V.C.

B. Annual Reports

Arthrex shall submit a written report to OIG on its compliance with the CIA requirements for each of the five Reporting Periods (Annual Report). Each Annual Report shall include, at a minimum, the following information:

1. any change in the identity, position description, or other noncompliance job responsibilities of the Compliance Officer; a current list of the Compliance Committee members; a current list of the Board members who are responsible for satisfying the Board compliance requirements; and a current list of the Certifying Employees, along with the identification of any changes made during the Reporting Period to the Compliance Committee, Board, and Certifying Employees;

2. a description of any changes to the written process for Certifying Employees to follow in order to complete the certification required by Section III.A.4;

3. the dates of each report made by the Compliance Officer to the Board (written documentation of such reports shall be made available to OIG upon request);
4. a description of the documents and other materials reviewed by the Board, as well as any additional steps taken, in its oversight of the compliance program and in support of making the resolution required by Section III.A.3;

5. a copy of the Compliance Program Review Report required by Section III.A.4;

6. a list of any new or revised Policies and Procedures required by Section III.B.1 developed during the Reporting Period;

7. a description of any changes to Arthrex’s Training Plan developed pursuant to Section III.C and a summary of any Board of Directors training provided during the Reporting Period;

8. a description of any changes to the risk assessment and internal review process required by Section III.D, including the reasons for such changes;

9. a summary of the following components of the risk assessment and internal review process during the Reporting Period: (a) work plans developed; (b) internal audits performed; (c) corrective action plans developed in response to internal audits; and (d) steps taken to track the implementation of the corrective action plans. Copies of any work plans, internal audit reports, and corrective action plans shall be made available to OIG upon request;

10. a complete copy of all reports prepared pursuant to Section III.E and Arthrex’s response to the reports, along with corrective action plan(s) related to any issues raised by the reports;

11. a certification from the IRO regarding its professional independence and objectivity with respect to Arthrex, including a summary of all current and prior engagements between Arthrex and the IRO;

12. a summary of the disclosures in the disclosure log required by Section III.F that relate to Federal health care programs, FDA requirements, or Government Reimbursed Products, including at least the following information: (a) a description of the disclosure, (b) the date the disclosure was received, (c) the resolution of the disclosure, and (d) the date the disclosure was resolved (if applicable). The complete disclosure log shall be made available to OIG upon request;

13. a description of any changes to the Ineligible Persons screening and removal process required by Section III.G, including the reasons for such changes;

Arthrex CIA
14. a summary describing any ongoing investigation or legal proceeding required to have been reported pursuant to Section III.H. The summary shall include a description of the allegation, the identity of the investigating or prosecuting agency, and the status of such investigation or legal proceeding;

15. a summary of Reportable Events (as defined in Section III.I) identified during the Reporting Period;

16. a summary describing any written communication with the FDA required to have been reported pursuant to Section III.J. This summary shall include a description of each matter and the status of each matter;

17. a summary of any changes to the policies, procedures, and systems relating to the Requirements Relating to Speaker Programs described in Section III.K, including the reasons for such changes;

18. the results of the FFMP required by Section III.L, including copies of the Observations for any instances in which it was determined that improper conduct occurred and a description of the action(s) that Arthrex took as a result of such determinations;

19. a summary of any changes to the policies, procedures, and systems relating to the Requirements for Certain Non-Promotional Activities described in Section III.M, including the reasons for such changes;

20. a certification from the Compliance Officer that information regarding Payments has been posted on Arthrex’s website as required by Section III.N;

21. a description of all changes to the most recently provided list of Arthrex’s locations (including addresses) as required by Section V.A.16;

22. a description of any changes to Arthrex’s corporate structure, including any parent and sister companies, subsidiaries, and their respective lines of business; and

23. the certifications required by Section V.C.

The first Annual Report shall be received by OIG no later than 60 days after the end of the first Reporting Period. Subsequent Annual Reports shall be received by OIG no later than the anniversary date of the due date of the first Annual Report.

_Arthrex CIA_
C. Certifications

1. Certifying Employees. In each Annual Report, Arthrex shall include the certifications of Certifying Employees as required by Section III.A.4;

2. Compliance Officer, President, and Senior Vice President and General Counsel. The Implementation Report and each Annual Report shall include a certification by the Compliance Officer, President, and the Senior Vice President and General Counsel that:

   a. to the best of his or her knowledge, except as otherwise described in the report, Arthrex has implemented and complies with is in compliance with all requirements of this CIA;

   b. he or she has reviewed the report and has made reasonable inquiry regarding its content and believes that the information in the report is accurate and truthful; and

   c. he or she understands that the certification is being provided to and relied upon by the United States.

D. Designation of Information

Arthrex shall clearly identify any portions of its submissions that it believes are trade secrets, or information that is commercial or financial and privileged or confidential, and therefore potentially exempt from disclosure under the Freedom of Information Act (FOIA), 5 U.S.C. § 552. Arthrex shall refrain from identifying any information as exempt from disclosure if that information does not meet the criteria for exemption from disclosure under FOIA.

VI. NOTIFICATIONS AND SUBMISSION OF REPORTS

Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities:

OIG:

Administrative and Civil Remedies Branch
Office of Counsel to the Inspector General

Arthrex CIA
Office of Inspector General  
U.S. Department of Health and Human Services  
Cohen Building, Room 5527  
330 Independence Avenue, S.W.  
Washington, DC 20201  
Telephone: (202) 619-2078

Arthrex:

Peter Jensen  
Vice President – Risk Management & Compliance, Chief Compliance Officer  
1370 Creekside Boulevard  
Naples, Florida 34108-1945  
Telephone: (800) 933-7001  
Email Address: peter.jensen@arthrex.com

Unless otherwise specified, all notifications and reports required by this CIA may be made by electronic mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. Upon request by OIG, Arthrex may be required to provide OIG with an additional copy of each notification or report required by this CIA in OIG’s requested format (electronic or paper).

VII. OIG INSPECTION, AUDIT, AND REVIEW RIGHTS

In addition to any other rights OIG may have by statute, regulation, or contract, OIG or its duly authorized representative(s) may conduct interviews, examine and/or request copies of or copy Arthrex’s books, records, and other documents and supporting materials and/or conduct on-site reviews of any of Arthrex’s locations for the purpose of verifying and evaluating: (a) Arthrex’s compliance with the terms of this CIA and (b) Arthrex’s compliance with Federal health care program requirements and with all applicable FDA requirements. The documentation described above shall be made available by Arthrex to OIG or its duly authorized representative(s) at all reasonable times for inspection, audit, and/or reproduction. Furthermore, for purposes of this provision, OIG or its duly authorized representative(s) may interview any of Arthrex’s owners, employees, contractors and directors who consent to be interviewed at the individual’s place of business during normal business hours or at such other place and time as may be mutually agreed upon between the individual and OIG. Arthrex shall assist OIG or its duly authorized representative(s) in contacting and arranging interviews with such individuals upon OIG’s request. Arthrex’s owners, employees, contractors and directors may elect to be interviewed with or without a representative of Arthrex present.

Arthrex CIA
VIII. DOCUMENT AND RECORD RETENTION

Arthrex shall maintain for inspection all documents and records relating to reimbursement from the Federal health care programs and to compliance with this CIA for six years (or longer if otherwise required by law) from the Effective Date.

IX. DISCLOSURES

Consistent with HHS’s FOIA procedures, set forth in 45 C.F.R. Part 5, OIG shall make a reasonable effort to notify Arthrex prior to any release by OIG of information submitted by Arthrex pursuant to its requirements under this CIA and identified upon submission by Arthrex as trade secrets, or information that is commercial or financial and privileged or confidential, under the FOIA rules. With respect to such releases, Arthrex shall have the rights set forth at 45 C.F.R. § 5.42(a).

X. BREACH AND DEFAULT PROVISIONS

A. Stipulated Penalties

OIG may assess:

1. A Stipulated Penalty of up to $2,500 for each day Arthrex fails to comply with Section III.A;

2. A Stipulated Penalty of up to $2,500 for each day Arthrex fails to comply with Section III.B;

3. A Stipulated Penalty of up to $2,500 for each day Arthrex fails to comply with Section III.C;

4. A Stipulated Penalty of up to $2,500 for each day Arthrex fails to comply with Section III.D;

5. A Stipulated Penalty of up to $2,500 for each day Arthrex fails to comply with Section III.E;

6. A Stipulated Penalty of up to $2,500 for each day Arthrex fails to comply with Section III.F;

7. A Stipulated Penalty of up to $2,500 for each day Arthrex fails to

Arthrex CIA
comply with Section III.G;

8. A Stipulated Penalty of up to $2,500 for each day Arthrex fails to comply with Section III.H;

9. A Stipulated Penalty of up to $2,500 for each day Arthrex fails to comply with Section III.I;

10. A Stipulated Penalty of up to $2,500 for each day Arthrex fails to comply with Section III.J;

11. A Stipulated Penalty of up to $2,500 for each day Arthrex fails to comply with Section III.K;

12. A Stipulated Penalty of up to $2,500 for each day Arthrex fails to comply with Section III.L;

13. A Stipulated Penalty of up to $2,500 for each day Arthrex fails to comply with Section III.M;

14. A Stipulated Penalty of up to $2,500 for each day Arthrex fails to comply with Section III.N;

15. A Stipulated Penalty of up to $2,500 for each day Arthrex fails to comply with Section IV;

16. A Stipulated Penalty of up to $2,500 for each day Arthrex fails to comply with Section V;

17. A Stipulated Penalty of up to $2,500 for each day Arthrex fails to comply with Section VII;

18. A Stipulated Penalty of up to $2,500 for each day Arthrex fails to comply with Section VIII; or

19. A Stipulated Penalty of up to $50,000 for each false certification or false statement made to OIG by or on behalf of Arthrex under this CIA.

*Arthrex CIA*
B. **Timely Written Requests for Extensions**

Arthrex may, in advance of the due date, submit a timely written request for an extension of time to perform any act or file any notification or report required by this CIA. If OIG grants the timely written request with respect to an act, notification, or report, Stipulated Penalties for failure to perform the act or file the notification or report shall not begin to accrue until one day after Arthrex fails to meet the revised deadline set by OIG. If OIG denies such a timely written request, Stipulated Penalties for failure to perform the act or file the notification or report shall not begin to accrue until three business days after Arthrex receives OIG’s written denial of such request or the original due date, whichever is later. A “timely written request” is defined as a request in writing received by OIG at least five business days prior to the date by which any act is due to be performed or any notification or report is due to be filed.

C. **Payment of Stipulated Penalties**

1. **Demand Letter.** If OIG determines that a basis for Stipulated Penalties under Section X.A exists, OIG shall notify Arthrex of: (a) Arthrex’s failure to comply; and (b) OIG’s demand for payment of Stipulated Penalties (this notification is referred to as the “Demand Letter”).

2. **Response to Demand Letter.** Within 15 business days after the date of the Demand Letter, Arthrex shall either: (a) pay the applicable Stipulated Penalties or (b) request a hearing before an HHS administrative law judge (ALJ) to dispute OIG’s determination of noncompliance, pursuant to the agreed upon provisions set forth below in Section X.E.

3. **Form of Payment.** Payment of the Stipulated Penalties shall be made by electronic funds transfer to an account specified by OIG in the Demand Letter.

D. **Exclusion for Material Breach of this CIA**

1. **Definition of Material Breach.** A material breach of this CIA means:

   a. failure to comply with any of the requirements of this CIA for which OIG has previously issued a demand for Stipulated Penalties under Section X.C;

   b. failure to comply with Section III.A.1;

*Arthrex CIA*
c. failure to comply with Section III.E;
d. failure to comply with Section III.I;
e. failure to comply with Section V;
f. failure to respond to a Demand Letter in accordance with Section X.C;
g. failure to pay Stipulated Penalties within 20 days after an ALJ issues a decision ordering Arthrex to pay the Stipulated Penalties or within 20 days after the HHS Departmental Appeals Board (DAB) issues a decision upholding the determination of OIG; or
h. failure to come into compliance with a requirement of this CIA for which OIG has demanded Stipulated Penalties, pursuant to the deadlines listed in Section X.E.2.

2. **Notice of Material Breach and Intent to Exclude.** The parties agree that a material breach of this CIA by Arthrex constitutes an independent basis for Arthrex’s exclusion from participation in the Federal health care programs. The length of the exclusion shall be in OIG’s discretion, but not more than five years for each material breach. Upon a preliminary determination by OIG that Arthrex has materially breached this CIA, OIG shall notify Arthrex of: (a) Arthrex’s material breach; and (b) OIG’s intent to exclude Arthrex (this notification is hereinafter referred to as the “Notice of Material Breach and Intent to Exclude”).

3. **Response to Notice.** Arthrex shall have 30 days from the date of the Notice of Material Breach and Intent to Exclude to submit any information and OIG to consider before it makes a final determination regarding exclusion.

4. **Exclusion Letter.** If OIG determines that exclusion is warranted, OIG shall notify Arthrex in writing of its determination to exclude Arthrex (this letter shall be referred to hereinafter as the “Exclusion Letter”). Subject to the Dispute Resolution provisions in Section X.E, below, the exclusion shall go into effect 30 days after the date of the Exclusion Letter. The exclusion shall have national effect. The effect of the exclusion shall be that no Federal health care program payment may be made for any items or services furnished, ordered, or prescribed by Arthrex, including administrative and management services, except as stated in regulations found at 42 C.F.R. §1001.1901(c). Reinstatement to program participation is not automatic. At the

*Arthrex CIA*
end of the period of exclusion, Arthrex may apply for reinstatement by submitting a written request for reinstatement in accordance with the provisions at 42 C.F.R. §§ 1001.3001-.3004.

E. Dispute Resolution

1. **Review Rights.** Upon OIG’s issuing a Demand Letter or Exclusion Letter, and as an agreed-upon remedy for the resolution of disputes arising under this CIA, Arthrex shall be afforded certain review rights comparable to the ones that are provided in 42 U.S.C. § 1320a-7(f) and 42 C.F.R. Part 1005. Specifically, OIG’s determination to demand payment of Stipulated Penalties or to seek exclusion shall be subject to review by an HHS ALJ and, in the event of an appeal, the DAB, in a manner consistent with the provisions in 42 C.F.R. § 1005.2-1005.21, but only to the extent this CIA does not provide otherwise. Notwithstanding the language in 42 C.F.R. § 1005: (a) the request for a hearing involving Stipulated Penalties shall be made within 15 business days after the date of the Demand Letter and the request for a hearing involving exclusion shall be made within 25 days after the date of the Exclusion Letter; and (b) no discovery shall be available to the parties. The procedures relating to the filing of a request for a hearing can be found at [http://www.hhs.gov/dab/divisions/civil/procedures/divisionprocedures.html](http://www.hhs.gov/dab/divisions/civil/procedures/divisionprocedures.html).

2. **Stipulated Penalties Review.** Notwithstanding any provision of Title 42 of the United States Code or Title 42 of the Code of Federal Regulations, the only issues in a proceeding for Stipulated Penalties under this CIA shall be: (a) whether Arthrex was in full and timely compliance with the requirements of this CIA for which OIG demands payment; and (b) the period of noncompliance. Arthrex shall have the burden of proving its full and timely compliance. If the ALJ upholds the OIG’s determination that Arthrex has breached this CIA and orders Arthrex to pay Stipulated Penalties, Arthrex must (a) come into compliance with the requirement(s) of this CIA that resulted in the OIG imposing Stipulated Penalties, and (b) pay the Stipulated Penalties within 20 days after the ALJ issues a decision, unless Arthrex properly and timely requests review of the ALJ decision by the DAB. If the ALJ decision is properly and timely appealed to the DAB and the DAB upholds the determination of OIG, Arthrex must (a) come into compliance with the requirement(s) of this CIA that resulted in the OIG imposing Stipulated Penalties, and (b) pay the Stipulated Penalties within 20 days after the DAB issues its decision.

3. **Exclusion Review.** Notwithstanding any provision of Title 42 of the United States Code or Title 42 of the Code of Federal Regulations, the only issues in a proceeding for exclusion based on a material breach of this CIA shall be whether Arthrex was in material breach of this CIA. If the ALJ sustains the OIG’s determination of

*Arthrex CIA*
material breach, the exclusion shall take effect 20 days after the ALJ issues the decision. If the DAB finds in favor of OIG after an ALJ decision adverse to OIG, the exclusion shall take effect 20 days after the DAB decision. Arthrex shall waive its right to any notice by OIG of the exclusion if a decision upholding the exclusion is rendered by the ALJ or DAB. If the DAB finds in favor of Arthrex, Arthrex shall be reinstated effective on the date of the exclusion.

4. **Finality of Decision.** The review by an ALJ or DAB provided for above shall not be considered to be an appeal right arising under any statutes or regulations. The parties to this CIA agree that the DAB’s decision (or the ALJ’s decision if not appealed) shall be considered final for all purposes under this CIA and Arthrex agrees not to seek additional review of the DAB’s decision (or the ALJ’s decision if not appealed) in any judicial forum.

**XI. EFFECTIVE AND BINDING AGREEMENT**

Arthrex and OIG agree as follows:

A. This CIA shall become final and binding on the date the final signature is obtained on the CIA.

B. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA.

C. All requirements and remedies set forth in this CIA are in addition to and do not affect (1) Arthrex’s responsibility to follow all applicable Federal health care program and FDA requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program or FDA requirements.

D. The undersigned Arthrex signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatories represent that they are signing this CIA in their official capacity and that they are authorized to execute this CIA.

E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Electronically-transmitted signatures shall constitute acceptable, binding signatures for purposes of this CIA.
ON BEHALF OF ARTHREX, INC.

/Peter Jensen/ 11/4/21
PETER JENSEN
Vice President, Risk Management and Compliance
Chief Compliance Officer
Arthrex, Inc.

/Jack W. Pirozzolo/ 11/4/2021
JACK W. PIROZZOLO
Counsel for Arthrex
Sidley Austin LLP
ON BEHALF OF THE OFFICE OF INSPECTOR GENERAL
OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES

/Lisa M. Re/                      11/5/2021
LISA M. RE
Assistant Inspector General for Legal Affairs
Office of Inspector General
U.S. Department of Health and Human Services

/Tonya Keusseyan/                 11/8/2021
TONYA KEUSSEYAN
Senior Counsel
Administrative and Civil Remedies Branch
Office of Counsel to the Inspector General
U.S. Department of Health and Human Services

Arthrex CIA
This Appendix contains the requirements relating to the Independent Review Organization (IRO) required by Section III.E of the CIA.

A. IRO Engagement

1. Arthrex shall engage an IRO that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the review in a professionally independent and objective fashion, as set forth in Paragraph E. Within 30 days after OIG receives the information identified in Section V.A.8 of the CIA or any additional information submitted by Arthrex in response to a request by OIG, whichever is later, OIG will notify Arthrex if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Arthrex may continue to engage the IRO.

2. If Arthrex engages a new IRO during the term of the CIA, that IRO must also meet the requirements of this Appendix. If a new IRO is engaged, Arthrex shall submit the information identified in Section V.A.8 of the CIA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by Arthrex at the request of OIG, whichever is later, OIG will notify Arthrex if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Arthrex may continue to engage the IRO.

B. IRO Qualifications

The IRO shall:

1. assign individuals to conduct the IRO Reviews who have expertise in the medical device industry and in all applicable Federal health care program and FDA requirements relating to the Covered Functions, including but not limited to expertise relating to marketing and promotional activities associated with medical devices and the Federal Anti-Kickback Statute and False Claims Act.

2. assign individuals to design and select the samples for the IRO Transactions Review who are knowledgeable about the appropriate statistical sampling techniques; and

3. have sufficient staff and resources to conduct the reviews required by the CIA on a timely basis.
C. **IRO Responsibilities**

The IRO shall:

1. perform each component of the IRO Reviews in accordance with the specific requirements of the CIA;

2. follow all applicable Federal health care program and FDA requirements in making assessments in the IRO Reviews;

3. respond to all OIG inquires in a prompt, objective, and factual manner; and

4. prepare timely, clear, well-written reports that include all the information required by Appendix B to the CIA.

D. **Arthrex Responsibilities**

Arthrex shall ensure that the IRO has access to all records and personnel necessary to complete the reviews listed in III.E of this CIA and that all records furnished to the IRO are accurate and complete.

E. **IRO Independence and Objectivity**

The IRO must perform each component of the IRO Reviews in a professionally independent and objective fashion, as defined in the most recent Government Auditing Standards issued by the U.S. Government Accountability Office.

F. **IRO Removal/Termination**

1. **Arthrex and IRO.** If Arthrex terminates its IRO or if the IRO withdraws from the engagement during the term of the CIA, Arthrex must submit a notice explaining (a) its reasons for termination of the IRO or (b) the IRO’s reasons for its withdrawal to OIG, no later than 30 days after termination or withdrawal. Arthrex must engage a new IRO in accordance with Paragraph A of this Appendix and within 60 days of termination or withdrawal of the IRO.

2. **OIG Removal of IRO.** In the event OIG has reason to believe the IRO does not possess the qualifications described in Paragraph B, is not independent and objective as set forth in Paragraph E or has failed to carry out its responsibilities as described in Paragraph C, OIG shall notify Arthrex in writing regarding OIG’s basis for determining that the IRO has not met the requirements of this Appendix. Arthrex shall have 30 days from the date of OIG’s written notice to provide information regarding the IRO’s qualifications, independence or performance of its responsibilities in order to resolve the
concerns identified by OIG. If, following OIG’s review of any information provided by Arthrex regarding the IRO, OIG determines that the IRO has not met the requirements of this Appendix, OIG shall notify Arthrex in writing that Arthrex shall be required to engage a new IRO in accordance with Paragraph A of this Appendix. Arthrex must engage a new IRO within 60 days of its receipt of OIG’s written notice. The final determination as to whether or not to require Arthrex to engage a new IRO shall be made at the sole discretion of OIG.
APPENDIX B

INDEPENDENT REVIEW ORGANIZATION REVIEWS

A. IRO Engagement, General Description

As specified more fully below, Arthrex shall retain an IRO to perform engagements to assist Arthrex in assessing and evaluating certain of its systems, processes, policies, and procedures related to Arthrex’s Covered Functions (as defined in Section II.C.3 of the CIA) (IRO Review). The IRO Review shall consist of two components—a systems review (Systems Review) and a transactions review (Transactions Review) as described more fully below. Arthrex may engage, at its discretion, a single entity to perform both components of the IRO Reviews, provided that the entity has the necessary expertise and capabilities to perform both.

If there are no material changes in Arthrex’s systems, processes, policies, and procedures relating to Covered Functions, the IRO shall perform the Systems Review of certain systems, processes, policies and procedures relating to Covered Functions (as set forth below) for the first and fourth Reporting Periods. If Arthrex materially changes its systems, processes, policies, and procedures relating to Covered Functions, the IRO shall perform a Systems Review for the Reporting Period(s) in which such changes were made in addition to conducting the Review as set forth above. The additional Systems Review(s) shall consist of: (1) an identification of the material changes, and (2) a review of the systems, processes, policies, and procedures that materially changed. The IRO shall conduct the Transactions Review for each Reporting Period of the CIA.

B. IRO Systems Review

The Systems Review shall be a review of Arthrex’s systems, processes, policies, and procedures (including the controls on those systems, processes, policies, and procedures) relating to Covered Functions. More specifically, the IRO shall review Arthrex’s systems, processes, policies, and procedures associated with the following (hereafter “Reviewed Policies and Procedures”):

1. Arthrex’s systems, policies, processes, and procedures relating to conducting Covered Functions in compliance with (a) applicable Federal health care program requirements, including but not limited to the Federal Anti-Kickback Statute, and the False Claims Act; and (b) all applicable FDA requirements;

2. Arthrex’s systems, policies, processes, and procedures relating to the materials and information that may be distributed by Arthrex sales representatives (including any contract sales force) about Government Reimbursed Products and the
manner in which Arthrex sales representatives respond to requests for information about
uses of Government Reimbursed Products that are not FDA approved, cleared, or exempt
(“non-FDA approved uses”);

3. Arthrex’s systems, policies, processes, and procedures relating to the
materials and information that may be distributed and the mechanisms through, and
manner in which, Arthrex receives and responds to requests for information from an HCP
or another individual or entity about non-FDA approved uses of Government Reimbursed
Products; the form and content of information disseminated by Arthrex in response to
such requests; and the internal review process for the information disseminated;

4. Arthrex’s systems, policies, processes, and procedures relating to the
manner and circumstances under which Arthrex medical personnel interact with or
participate in meetings or events with HCPs, HCIs, or payors (either alone or with
Arthrex sales representatives) and the role of Arthrex medical personnel at such meetings
or events, as well as how they handle responses to requests for information about non-
FDA approved uses of Government Reimbursed Products;

5. Arthrex’s systems, policies, processes, and procedures relating to the
materials and information that may be distributed or made available by Arthrex through
social media and/or direct-to-consumer advertising;

6. Arthrex’s systems, policies, processes, and procedures relating to the
development, implementation, and review of all polices for the distribution of
Government Reimbursed Products for evaluation purposes (Evaluation Product). This
shall include a review of the bases upon, and circumstances under, which HCPs and HCIs
belonging to specified medical specialties or types of clinical practice may receive
Evaluation Product from Arthrex (including, separately, from sales representatives, or
through other channels);

7. Arthrex’s systems, policies, processes, and procedures relating to consultant
or other fee-for-service arrangements entered into with HCPs or HCIs (including but not
limited to speaker programs, speaker training programs, training and education services,
product development activities, presentations, consultant task force meetings, advisory
boards, ad hoc advisory activities, research and research-related activities, authorship
activities, and any other financial engagement or arrangement with an HCP or HCI) and
all events and expenses relating to such engagements or arrangements;

8. Arthrex’s systems, policies, processes, and procedures relating to
agreements or arrangements with HCPs or HCIs for the purchase or licensing of
intellectual property or for the payment of royalties for intellectual property contributions
to the development of a product, technology, process, or method;

Arthrex CIA - Appendix B
9. Arthrex’s systems, policies, processes, and procedures relating to programs by HCPs to educate sales representatives, including but not limited to presentations by HCPs at sales meetings, preceptorships, tutorials, and experience-based learning activities;

10. Arthrex’s systems, policies, processes, and procedures relating to the review and approval of, and payment for, travel and related expenses for HCPs including those in connection with an HCP’s participation in educational, research, training, or other Arthrex-sponsored programs or activities;

11. Arthrex’s systems, policies, processes, and procedures relating to the sponsorship or funding of grants (including educational grants) or charitable contributions involving HCPs or HCIs;

12. Arthrex’s systems, policies, processes, and procedures relating to funding of, or participation in, any Sponsorships or Third-Party Educational Activity as defined in Section II.C.4 and II.C.5 of the CIA;

13. Arthrex’s systems, policies, processes, and procedures relating to the review of promotional, reimbursement-related, and disease state materials and information intended to be disseminated outside Arthrex by appropriate qualified personnel (such as regulatory, medical, and/or legal personnel) in a manner designed to ensure that legal, regulatory, and medical concerns are properly addressed during Arthrex’s review and approval process and are elevated when appropriate;

14. Arthrex’s systems, policies, processes, and procedures relating to compensation (including through salaries, bonuses, or other means) for Covered Persons who are sales representatives and their managers; and

15. Arthrex’s systems, policies, processes, and procedures relating to disciplinary policies and procedures for violations of Arthrex’s Policies and Procedures, including policies relating to Federal health care program and FDA requirements.

C. IRO Systems Review Report

The IRO shall prepare a report based upon each Systems Review performed. For each of the Reviewed Policies and Procedures identified in Section B above, the report shall include the following items:

1. a description of the documentation (including policies) reviewed and any personnel interviewed;
2. a detailed description of Arthrex’s systems, policies, processes, and procedures relating to the items identified in Sections B.1-15 above, including a general description of Arthrex’s control and accountability systems (e.g., documentation and approval requirements, and tracking mechanisms) and written policies regarding the Reviewed Policies and Procedures;

3. a description of the manner in which the control and accountability systems and the written policies relating to the items identified in Sections B.1-15 above are made known or disseminated within Arthrex;

4. findings and supporting rationale regarding any weaknesses in Arthrex’s systems, processes, policies, and procedures relating to the Reviewed Policies and Procedures, if any; and

5. recommendations to improve any of the systems, policies, processes, or procedures relating to the Reviewed Policies and Procedures, if any.

D. IRO Transactions Review

The Transactions Review shall include a review of: (1) a sample of consultant or other fee-for-service arrangements entered into with HCPs (including all events and expenses related to such engagements or arrangements), (2) a sample of agreements with HCPs or HCIs for the purchase or licensing of intellectual property involving HCPs and HCIs, and (3) a sample of Payments. The IRO shall report on all aspects of its reviews in the Transactions Review Report.

1. Review of Consulting Activities. For purposes of this Appendix B, the term “Consulting Activities” shall include all consulting and other fee for service arrangements entered with HCPs (including but not limited to speaker programs, speaker training programs, training and education services, product development activities, presentations, consultant task force meetings, advisory boards, ad hoc advisory activities, research and research-related activities, authorship and authorship-related activities, and any other financial engagement or arrangement with an HCP or HCI) and all events and expenses relating to such engagements or arrangements.

   a. For the first Reporting Period, the IRO shall randomly select and review a sample of 25 Consulting Activities entered into with HCPs and all related expenses. For the second and subsequent Reporting Periods, within 60 days prior to the end of the applicable Reporting Period, Arthrex shall provide the following information to the OIG: (1) a description of each type of Consulting Activity undertaken during the Reporting Period and a description of the services to be provided under each Consulting Activity; (2) the number of each
The type of Consulting Activity undertaken during the Reporting Period; and (3) the overall budgeted amount to be spent in connection with each type of Consulting Activity during the Reporting Period. The OIG shall select the number of each type of Consulting Activity to be reviewed by the IRO during the second and subsequent Reporting Periods, for a total sample size of 25 Consulting Activities.

c. For each Consulting Activity reviewed, the IRO shall determine whether:

i. a written agreement was in place for each Consulting Activity that describes the scope of work to be performed, the fees and related expenses to be paid for the Consulting Activity, and the compliance obligations for the Consultant;

ii. the compensation to be paid for the Consulting Activity was determined in accordance with a centrally managed, pre-set rate structure established by Arthrex based on an independent fair market value analysis;

iii. the Consulting Activity was identified in the annual Consultant budgeting plan developed by Arthrex;

iv. a needs assessment that identifies the business need for the Consulting Activity and provides details about the Consulting Activity was completed prior to the initiation of the Consulting Activity;

v. the Consulting Activity was reviewed and approved in accordance with Arthrex Policies and Procedures;

vi. Arthrex collected and retained a record of the specific activity performed by the HCP and, if applicable, a copy of the work product generated by the HCP in connection with the Consulting Activity; and

vii. the activity undertaken by the Consultant and/or the work product generated by the HCP was used by Arthrex in a manner consistent with the needs assessment that was completed prior to the initiation of the Consulting Activity.
2. **Review of Intellectual Property Arrangements.** For purposes of this Appendix B, the term “Intellectual Property Arrangement” shall include any agreement or arrangement with an HCP or HCI for the licensing or purchase of intellectual property or for the payment of royalties for intellectual property contributions to the development of a product, technology, process, or method.

a. For each Reporting Period, the IRO shall randomly select and review a sample of ten Intellectual Property Arrangements.

b. For each Intellectual Property Arrangement reviewed, the IRO shall determine whether:

i. a written agreement was in place for each Intellectual Property Arrangement that describes the specific intellectual property to be licensed or purchased, or the intellectual property contribution made by the HCP or HCI, and the purchase price, licensing fees, or royalties to be paid;

ii. the purchase price, licensing fees, or royalty rates were determined based on an independent fair market value analysis;

iii. the HCP or HCI party to the Intellectual Property Arrangement is as an inventor on a patent application or issued patent relating to the purchased or licensed intellectual property;

iv. the determination of whether the HCP or HCI made a novel, significant, or innovative intellectual property contribution to the development of a product, technology, process or method, was made according to Arthex’s internal Policies and Procedures and there is documentation of the determination.

v. the Intellectual Property Arrangement is consistent with the annual budgeting plan developed by Arthrex;

vi. a needs assessment that identifies the business need for the Intellectual Property Arrangement and provides details about the arrangement was completed and documented prior to entering into the Intellectual Property Arrangement; and
vii. the Intellectual Property Arrangement was reviewed and approved in accordance with Arthrex’s Policies and Procedures.

3. **Review of Payments.** For purposes of this Appendix B, the term “Control Documents” shall include all material documents or electronic records associated with each Arthrex Payment reflected in the Open Payments database for that calendar year. For example, the term “Control Documents” includes, but is not limited to, documents relating to the nature, purpose, and amount of the Payment; contracts relating to the Payment; documents relating to the occurrence of Payment; documents reflecting any work product generated in connection with the Payment; documents submitted by sales representatives or headquarters personnel to request approval for the Payment; and business rationale or justification forms relating to the Payment.

a. For each Reporting Period, the OIG shall have the discretion to identify up to 50 Covered Recipients who received Payments from Arthrex during the prior calendar year and will be subject to the IRO review described below. If the OIG elects to exercise this discretion, it shall notify the IRO of the Covered Recipients subject to the IRO Review. If the OIG elects not to exercise its discretion, the IRO shall randomly select 50 Covered Recipients to be included in the review.

b. For each selected Covered Recipient, the IRO shall review the Control Documents associated with the Payments to the Covered Recipient for all categories reflected in the Open Payments Data website except for the Food/Beverage and Travel/Lodging categories of Payments. Specifically, for each Covered Recipient selected as part of the sample, the IRO shall review the Control Documents identified by the IRO as necessary and sufficient to validate each Payment reported to CMS to evaluate the following:

i. whether Control Documents are available relating to each Payment;

ii. whether the Control Documents were completed and archived in accordance with the requirements set forth in Arthrex’s policies;

iii. whether the aggregate value of the Payment as reflected in the Open Payments Database is consistent with the value of the Payment reflected in the Control Documents; and
iv. whether the Control Documents reflect that Arthrex’s policies were followed in connection with the Payment (e.g., all required written approvals for the activity were obtained in accordance with Arthrex’s policies.)

E. Transactions Review Report

1. General Elements to be Included in the Report. For each Reporting Period, the IRO shall prepare a report based on its Transactions Review. The report shall include the following:

   a. Review Objectives: A clear statement of the objectives intended to be achieved by each part of the review;

   b. Review Protocol: A detailed narrative description of the procedures performed, and a description of the sampling unit and universe utilized in performing the procedures for each sample reviewed; and

   c. Sources of Data: A full description of documentation and other information, if applicable, relied upon by the IRO in performing the Transactions Review.

2. Results to be Included in Report. The following results shall be included in each Transactions Review Report:

   a. Relating to the Review of Consulting Activities

      i. a description of each type of Consulting Activity reviewed, including the number of each type of Consulting Activity reviewed and an identification of the types of documents and information reviewed for each Consulting Activity;

      ii. for each Consulting Activity reviewed, the IRO’s findings and supporting rationale as to whether:

         (a) a written agreement was in place for each Consulting Activity that describes the scope of work to be performed, the fees and expenses to be paid for each Consulting Activity, and the compliance obligations for the Consultant;
(b) the compensation to be paid for the Consulting Activity was determined in accordance with a centrally managed, pre-set rate structure set by Arthrex that was established based on an independent FMV analysis;

(c) the Consulting Activity was identified in the annual Consulting budgeting plan developed by Arthrex;

(d) a needs assessment that identifies the business need for the Consulting Activity and provides detail about the activity was prepared prior to the initiation of the Consulting Activity;

(e) the Consulting Activity was reviewed and approved in accordance with Arthrex Policies and Procedures,

(f) Arthrex collected and retained a record of the specific activity performed by the HCP and, if applicable, a copy of the work product generated in connection with the Consulting Activity; and

(g) the activity undertaken by the Consultant and/or the work product generated was used by Arthrex in a manner consistent with the needs assessment that was completed prior to the initiation of the Consulting Activity.

iii. any weaknesses in Arthrex’s systems, processes, policies, procedures and/or practices relating to Consulting Activities identified by the IRO; and

iv. any recommendations for improvements to Arthrex’s systems, processes, policies, procedures and/or practices relating to Consulting Activities.

b. Relating to the Review of Intellectual Property Arrangements

i. a description of each Intellectual Property Arrangement reviewed, and an identification of the types of documents and information reviewed for each Intellectual Property Arrangement;
for each Intellectual Property Arrangement reviewed, the IRO’s findings and supporting rationale as to whether:

(a) a written agreement was in place for each Intellectual Property Arrangement that describes the specific intellectual property to be licensed or purchased, or the intellectual property contribution made by the HCP or HCI and the purchase price, licensing fees, or royalties to be paid;

(b) the determination of whether the HCP or HCI made a novel, significant, or innovative intellectual property contribution to the development of a product, technology, process or method, was made and documented according to Arthrex’s internal Policies and Procedures;

(c) if applicable, Arthrex has documented that the HCP or HCI party to the Intellectual Property Arrangement is as an inventor on a patent application or issued patent relating to the purchased or licensed intellectual property

(d) the royalty amounts were determined based on an independent fair market value analysis;

(e) the Intellectual Property Arrangement is consistent with the annual budgeting plan developed by Arthrex;

(f) a needs assessment that identifies the business need for the Intellectual Property Arrangement and provides details about the arrangement was prepared prior to entering into the arrangement; and

(g) the Intellectual Property Arrangement was reviewed and approved in accordance with Arthrex’s Policies and Procedures.

iv. any weaknesses in Arthrex’s systems, processes, policies, procedures and/or practices relating to Intellectual Property Arrangements identified by the IRO; and
v. any recommendations for improvements to Arthrex’s systems, processes, policies, procedures and/or practices relating to Intellectual Property Arrangements.

c. Relating to the Review of Payments

i. a description of the entry in the Open Payments Database for each Payment sampled and a description of Control Documents reviewed in connection with each sampled Payment; and

ii. for each sampled Payment, findings and supporting rationale as to whether:

   (a) all required Control Documents exist;

   (b) each Control Document was completed in accordance with all of the requirements set forth in the applicable Arthrex policy;

   (c) the aggregate value of the Payment as reflected in the Open Payments Database is consistent with the value of the Payment reflected in the Control Documents;

   (d) each Control Document reflects that Arthrex’s policies were followed in connection with the underlying activity reflected in the document (all required approvals were obtained); and

   (e) any corrective action or disciplinary action was undertaken in those instances in which Arthrex policies were not followed.